Managing the risks of the Covid-19 pandemic remains a challenge. While EU vaccination rates have reached three quarters of the population, new SARS-CoV-2 variants keep emerging in the EU. Although these variants appear to be generally less severe, they still pose challenges to health systems. The implementation of a globally effective vaccine strategy remains key to enhancing Europe's resilience. If measures are successful, it is expected that SARS-CoV-19 – while still present – will enter a stage of seasonality, characterised by higher case numbers in the winter months, similarly to the flu. To achieve this, rethinking present surveillance and monitoring schemes, ensuring the distribution of vaccines worldwide and implementing an action plan against disinformation and misinformation could be crucial.

EPRS STOA podcast - Responding better to future pandemics

Sappiamo che i vaccini sono strumenti efficaci. Grazie al loro utilizzo siamo stati in grado di debellare malattie in passato mortali. Nella crisi del coronavirus l'Unione sta promuovendo la ricerca di un vaccino. Ecco come.

Cosa fa l'Europa per i ricercatori che sviluppano vaccini

<p>Vaccines are a key part of a long-term strategy to bring SARS-CoV-2 under control. It is essential to roll out vaccination rapidly to protect as many people as possible and to lower the opportunities for the virus to evolve further. Any vaccine must be authorised by the European Medicines Agency (EMA).</p>

<p>The European Commission has secured up to 4.4 billion doses of COVID-19 vaccines so far - and negotiations are underway for additional doses. However, countries are facing different challenges around the disinformation or vaccine acceptance. The European Parliament is trying to keep an eye on the purchase and safety of these vaccines. During June plenary the EP adopted a resolution calling for COVID-19 vaccine patent waiver. Parliament proposed negotiations start for a temporary waiver of the WTO TRIPS Agreement on patents to improve global access to affordable COVID-19-related medical products and to address global production constraints and supply shortages. The EP approved also the Digital Green Certificate to facilitate the safe free movement of citizens within the EU during the pandemic.</p>

EU Vaccine Strategy

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee - Exchange of views with external experts on COVID-19 vaccines

DEVE/AFET Commitees - Access to vaccines in developing countries - Exchange of views with the European Commission, EEAS and representatives of international organisation

Apertura della seduta

Comunicazione dei risultati della votazione

Sanzioni degli Stati Uniti e Stato di diritto (discussione)

Primo turno di votazioni

Sanzioni degli Stati Uniti e Stato di diritto

Repressione del governo nei confronti delle proteste e dei cittadini a Cuba

Il caso di Ahmed Mansoor, difensore dei diritti umani, negli Emirati Arabi Uniti

Situazione nel campo profughi di Kakuma in Kenya

Ripresa della seduta

Comunicazione dei risultati della votazione: vedasi processo verbale

Composizione delle commissioni e delle delegazioni 

Secondo turno di votazioni

Trasparenza dell&#39;UE sullo sviluppo, l&#39;acquisto e la distribuzione dei vaccini contro la COVID-19 (discussione)

Approvazione dei processi verbali della presente tornata e trasmissione dei testi adottati: vedasi processo verbale

Calendario delle prossime sedute: vedasi processo verbale

Chiusura della seduta

Interruzione della sessione

Plenary session

Affrontare la sfida globale della COVID-19: gli effetti della deroga all&#39;accordo TRIPS dell&#39;OMC sui vaccini, le terapie, i dispositivi e sull&#39;incremento delle capacità di produzione e fabbricazione nei paesi in via di sviluppo (discussione)

Conflitto di interessi del Primo ministro della Repubblica ceca (discussione)

Primo turno di votazioni (proseguimento)

Agenzia dell&#39;Unione europea per i diritti fondamentali: relazione interlocutoria (discussione)

Nuovi canali per la migrazione legale di manodopera (discussione)

Il futuro digitale dell&#39;Europa: mercato unico digitale e uso dell&#39;IA per i consumatori europei (discussione)

Responsabilità delle imprese per i danni ambientali (discussione)

Responsabilità delle imprese per i danni ambientali (discussione) (seguito della discussione)

L&#39;importanza della giustizia civile per la ripresa economica dopo la COVID-19 (discussione)

Ambiente: regolamento di Aarhus (discussione)

Centro europeo di competenza sulla cibersicurezza (discussione)

Programma &#34;Fiscalis&#34; per la cooperazione nel settore dell&#39;imposizione fiscale 2021-2027 (discussione)

Ordine del giorno della prossima seduta: vedasi processo verbale

Statements by Pascal CANFIN and by Cristian-Silviu BUŞOI, ITRE Chair on "COVID 19 vaccine production and delivery"

Webinar on Vaccines – A united response to beat the Covid-19 virus

Impatto delle misure connesse alla COVID-19 sulla democrazia, sui diritti fondamentali e sullo Stato di diritto (discussione)

Impatto delle misure connesse alla COVID-19 sulla democrazia, sui diritti fondamentali e sullo Stato di diritto (seguito della discussione)

Programma d&#39;azione dell&#39;Unione in materia di salute per il periodo 2021-2027 (&#34;programma &#39;UE per la salute&#39;&#34;) (EU4Health) (discussione)

Trasparenza in materia di acquisto di vaccini contro la COVID-19 e accesso agli stessi (discussione)

Composizione del Parlamento: vedasi processo verbale

Piano di investimenti per un&#39;Europa sostenibile - Come finanziare il Green Deal (discussione)

Elezione del primo Vicepresidente del Parlamento europeo (in sostituzione di Mairead McGuinness) (votazione): vedasi processo verbale

Composizione delle commissioni e delle delegazioni : vedasi processo verbale

Rettifiche (articolo 241 del regolamento) (seguito dato): vedasi processo verbale

Plenary Session

ENVI-ITRE Joint Hearing on "How to secure access to COVID-19 vaccines for EU citizens: clinical trials, production and distribution challenges"

ITRE

ENVI

Modifica dell'ordine del giorno: vedasi processo verbale

Legislazione di emergenza in Ungheria e suo impatto sullo Stato di diritto e i diritti fondamentali (discussione)

Legislazione di emergenza in Ungheria e suo impatto sullo Stato di diritto e i diritti fondamentali (seguito della discussione)

70° anniversario della Dichiarazione Schuman (discussione)

Utilizzo di applicazioni di tracciamento dei contatti nella lotta al coronavirus (discussione)

Vaccini e terapie nel contesto della Covid-19 (discussione)

Rettifica (articolo 2431 del regolamento) (seguito dato): vedasi processo verbale

Terzo turno di votazioni

Reticenza nei confronti dei vaccini e calo dei tassi di vaccinazione in Europa (discussione)

Vaccine hesitancy and drop in vaccination rates in Europe (debate)

Iniziativa sul vaccino contro la tubercolosi (discussione)

Tuberculosis Vaccine Initiative (debate)

Accesso limitato dei paesi in via di sviluppo ad alcuni vaccini (discussione)

Problem of limited access of developing countries to some vaccines (debate)

EP Plenary session  - EU transparency in the development, purchase and distribution of COVID-19 vaccines

EP Plenary session - Meeting the Global Covid 19 challenge: effects of waiver of the WTO TRIPS agreement on Covid-19 vaccines, treatment, equipment and manufacturing capacity in developing countries

Stockshot picture showing what could be a COVID-19 Green Certificate for traveling

ENVI Committee - Exchange of views with  Emer Cooke,EMA Executive Director, on the update of evaluation and authorisation of COVID-19 vaccines

ENVI Committee - COVID-19 variants and the vaccines' efficacy

ENVI- ITRE joint Committee -  Hearing on  ' How to increase the capacity of COVID 19 vaccine production and improve delivery 'Press point

ENVI- ITRE joint Committee -  Hearing on  ' How to increase the capacity of COVID 19 vaccine production and improve delivery '- Session 2

ENVI- ITRE joint Committee -  Hearing on  ' How to increase the capacity of COVID 19 vaccine production and improve delivery 'Session 1

ENVI- ITRE joint Committee -  Hearing on  ' How to increase the capacity of COVID 19 vaccine production and improve delivery '- Welcome and opening remarks

DEVE Committee - Access to COVID-19 vaccines for developing countries - exchange of views with Jutta URPILAINEN, Commissioner for International Partnerships

David SASSOLI, EP President in video meeting with Dr Franklin BERKLEY, CEO of The Vaccine Alliance

BUDG Committee - Financing from the EU budget in the context of the EU vaccines strategy

Statement by Pascal CANFIN, Chair of ENVI Committee on Vaccine deliveries and contracts transparency

Coronavirus - Vaccinations of healthcare professionals

ENVI - Committee on Environment, Public Health and Food Safety - Exchange of views with the Commission on the issue of vaccines in the EU

ENVI -  Committee on the Environment, Public Health and Food Safety - State of play with the assessment and authorization of vaccines against COVID-19 - Exchange of views with Emer COOKE, Executive Director of the European Medicines Agency (EMA)

Vaccination campaign

This infoclip shows how the European Parliament responded to COVID pandemic from March 2020 with distancing activities of the European Parliament held by David SASSOLI, EP President until the press conference to present the results of the work of the Committee on collecting the evidence and lessons learned from the COVID-19 pandemic as well as to give answers on the impact it had on citizens and their fundamental rights, the businesses, the health sector and international community in June 2023. This infoclip shows illustrations of EP buildings used in the fight against COVID-19, the Green corridor at the Belgium-Dutch border, digital COVID certificates, trilogue on the EU COVID-19 certificate, meetings of the Special COVI Committee, vaccines production and distribution, COVID-19 pandemic: lessons learned and recommendations for the future: extracts from the voteand from the press conference

European Parliament’s priorities and achievements (2019-2024): Response to COVID pandemic

Ahead of the 17-18 February European Union-African Union summit in Brussels, MEPs review the EU’s relations with Africa on Tuesday afternoon. The discussion focuses on the common challenges facing both continents, including the recovery from the COVID-19 pandemic, boosting vaccination and stimulating investments. Closing statement by Josep BORRELL, Vice-President of the Commission/High Representative of the Union for Foreign Affairs and Security Policy.

EU-Africa relations: closing statement by Josep BORRELL, Vice-President of the Commission/High Representative of the Union for Foreign Affairs and Security Policy

During the plenary session (13-16 September 2021) in the European Parliament in Strasbourg, MEPs participate in the debate on the EU transparency in the development, purchase and distribution of COVID-19 vaccines.

EU transparency in the development, purchase and distribution of COVID-19 vaccines - O.Q. to Commission: MEPs debate

During the plenary session (13-16 September 2021) in the European Parliament in Strasbourg, MEPs participate in the debate on the EU transparency in the development, purchase and distribution of COVID-19 vaccines. Opening statements by Dolors MONTSERRAT (EPP, ES), Author and by Ylva JOHANSSON, European Commissioner for Home Affairs on behalf of Stella KYRIAKIDES, European Commissioner for Health and Food Safety. This transcription speech is the result of an automatic process. Check against delivery.

EU transparency in the development, purchase and distribution of COVID-19 vaccines - O.Q. to Commission: opening statements by Dolors MONTSERRAT (EPP, ES), Author and by Ylva JOHANSSON, European Commissioner for Home Affairs

During the plenary session (13-16 September 2021) in the European Parliament in Strasbourg, MEPs participate in the debate on the EU transparency in the development, purchase and distribution of COVID-19 vaccines. Closing statement by Ylva JOHANSSON, European Commissioner for Home Affairs on behalf of Stella KYRIAKIDES, European Commissioner for Health and Food Safety.

EU transparency in the development, purchase and distribution of COVID-19 vaccines - O.Q. to Commission: closing statement by Ylva JOHANSSON, European Commissioner for Home Affairs

Announcement of the results of the voting session (09/06) during the plenary session (7-10 June 2021) in the European Parliament in Strasbourg. Final votes on the conflict of interest of the Czech Prime Minister and the agreement on Covid-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries and others. The results of the vote on the conflict of interest of the Czech Prime Minister are 690 voting - 505 in favour - 30 against - 155 abstentions. The results of the vote on WTO TRIPS (vaccine agreement) are 689 voting - 355 in favour - 263 against - and 71 abstentions.

Announcement of the results of the voting session (09/06): final votes on the conflict of interest of the Czech Prime Minister, and the agreement on Covid-19 vaccines and others

During the plenary session (7-10 June 2021) in the European Parliament in Strasbourg, MEPs debate on the conclusions of the special meeting of the European Council on 24 and 25 May 2021: extracts from the debates on EU Vaccines strategy. Statements by Charles MICHEL, President of the European Council, Ursula VON DER LEYEN, President of the EC, Manfred WEBER (EPP, DE), Iratxe GARCÍA PÉREZ (S&D, ES), Dacian CIOLOŞ (Renew, RO), Ska KELLER (Greens/EFA, DE), and Beata SZYDŁO (ECR, PL).

EU Vaccines strategy: extracts from the debate

Il Parlamento ha discusso dell'opportunità di rinunciare ai brevetti per i vaccini anti-Covid e ha adottato un programma Erasmus+ più inclusivo. Anche il clima era tra i temi all'ordine del giorno: il PE ha approvato il Fondo per una transizione giusta per aiutare le regioni ad adattarsi alla transizione verde e ha esortato l'UE a fare di più per proteggere gli attivisti ambientali. Il PE ha anche discusso dell'escalation del conflitto israelo-palestinese.

Plenaria, punti salienti: brevetti per i vaccini anti-Covid, Erasmus+ e ambiente

During the plenary session of the European Parliament in Brussels (17-20 May 2021), MEPs debate proposal to the WTO to waive intellectual property rights for COVID-19 vaccines, a move backed by the US administration. Extracts from the debate: statements by Augusto SANTOS SILVA, Portuguese Minister of State for Foreign Affairs, Valdis DOMBROVSKIS, Executive Vice-President of the EC in charge of an Economy that works for People, Esther de LANGE (EPP, NL), Iratxe GARCÍA PÉREZ (S&D, ES), Dacian CIOLOŞ (Renew, RO), Tilly METZ (Greens/EFA, LU), Marc BOTENGA (The Left, BE), and Gilles LEBRETON (ID, FR).

Waiver of the Global Covid 19 vaccines patents: extracts from the debate

During the plenary session of the European Parliament in Brussels (17-20 May 2021), MEPs debate on the meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: Closing statements by Valdis DOMBROVSKIS, Executive Vice-President of the European Commission in charge of an Economy that works for People, and Commissioner for Trade and by Augusto SANTOS SILVA, Portuguese Minister of State for Foreign Affairs

Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: Closing statements by Council and Comission

During the plenary session of the European Parliament in Brussels (17-20 May 2021), MEPs debate on the meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 1/3

Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 1/3

During the plenary session of the European Parliament in Brussels (17-20 May 2021), MEPs debate on the meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 3/3

Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 3/3

During the plenary session of the European Parliament in Brussels (17-20 May 2021), MEPs debate on the meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 2/3

Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 2/3

During the plenary session of the European Parliament in Brussels (17-20 May 2021), MEPs debate on the meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: Opening statements by Augusto SANTOS SILVA, Portuguese Minister of State for Foreign Affairs and by Valdis DOMBROVSKIS, Executive Vice-President of the European Commission in charge of an Economy that works for People, and Commissioner for Trade.

Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: Opening statements Council and Commission

Members of the Environment, Public Health and Food Safety (ENVI) Committee had an exchange of views on a new legislation for a faster authorisation procedure for COVID-19 vaccines that have already received EU authorisation, but which are being adapted to be effective against variants of the virus.

Quicker authorization procedure for adapted COVID-19 vaccines: exchange of views and statement by Cristian-Silviu BUŞOI (EPP, RO), Chair of the EP Committee on Industry, Research and Energy

The EU Digital COVID Certificate aimed to ensure the freedom of movement within the EU during the pandemic.The Certificate would constitute proof that a person has been either vaccinated against COVID-19, received a negative test result, or already recovered from the disease. This infoclip shows traveller presenting their Digital Certificate (fiction - posed scenes), people receiving the vaccine against COVID-19 and being tested.

Infoclip: EU Digital COVID Certificate (posed scenes)

During the plenary session (24-25 March 2021) in the European Parliament in Brussels, MEPs debate the export transparency and authorisation mechanism for COVID-19 vaccine after the European Commission has introduced the principles of reciprocity and proportionality as new criteria to be considered for authorising exports. Statements by Maros SEFCOVIC, Vice-President of the EC in charge of Interinstitutional relations and Foresight, Manfred WEBER (EPP, DE), Chair of the EPP Group, Iratxe GARCÍA PÉREZ (S&D, ES), Chair of the S&D Group, Katalin CSEH (Renew, HU), and Martin SCHIRDEWAN (The Left, DE), Co-chair of the Left Group.

Export transparency and authorisation mechanism of COVID19 vaccines: extracts

Emer COOKE, European Medicines Agency (EMA) Executive Director update MEPs from the Environment, Public Health and Food Security Committee on the state of play in the evaluation and market authorisation of vaccines against COVID-19 and the next steps. And Members of the Budgets Control Committee and the Commission’s Director-General for Health and Food Safety (SANTE), Sandra GALLINA, discuss the current state of the EU’s advance purchase agreement on vaccines against COVID-19.

Update of purchase, evaluation and authorization of COVID-19 vaccines: extracts from the exchanges of views with Sandra GALLINA, Director-General of DG SANTE (CONT) and with Emer COOKE, EMA Executive Director (ENVI)

Visualizzazione 707 risultati Foto per ""

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee - Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee - Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee - Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

DEVE/AFET Commitees - Access to vaccines in developing countries - Exchange of views with the European Commission, EEAS and representatives of international organisation

DEVE/AFET Commitees - Access to vaccines in developing countries - Exchange of views with the European Commission, EEAS and representatives of international organisation

DEVE/AFET Commitees - Access to vaccines in developing countries - Exchange of views with the European Commission, EEAS and representatives of international organisation

DEVE/AFET Commitees - Access to vaccines in developing countries - Exchange of views with the European Commission, EEAS and representatives of international organisation